Department of Medical Biochemistry, University of Nigeria Enugu Campus, Nsukka, Nigeria.
Department of Medical Laboratory Science, Faculty of Health Science and Technology, College of Medicine, University of Nigeria Enugu Campus, Enugu State, Nigeria.
Curr Clin Pharmacol. 2020;15(2):110-124. doi: 10.2174/1574884714666190905162237.
There may be a possible link between the use of HAART and oxidative stress-related mitochondrial dysfunction in HIV patients. We evaluated the mitochondrial and oxidative impacts of short and long-term administration of HAART on HIV patients attending the Enugu State University Teaching (ESUT) Hospital, Enugu, Nigeria following short and long-term therapy.
96 patients categorized into four groups of 24 individuals were recruited for the study. Group 1 comprised of age-matched, apparently healthy, sero-negative individuals (the No HIV group); group 2 consisted of HIV sero-positive individuals who had not started any form of treatment (the Treatment naïve group). Individuals in group 3 were known HIV patients on HAART for less than one year (Short-term treatment group), while group 4 comprised of HIV patients on HAART for more than one year (Long-term treatment group). All patients were aged between 18 to 60 years and attended the HIV clinic at the time of the study. Determination of total antioxidant status (TAS in nmol/l), malondialdehyde (MDA in mmol/l), CD4+ count in cells/μl, and genomic studies were all done using standard operative procedures.
We found that the long-term treatment group had significantly raised the levels of MDA, as well as significantly diminished TAS compared to the Short-term treatment and No HIV groups (P<0.05). In addition, there was significantly elevated variation in the copy number of mitochondrial genes (mtDNA: D-loop, ATPase 8, TRNALEU uur) in the long-term treatment group.
Long-term treatment with HAART increases oxidative stress and causes mitochondrial alterations in HIV patients.
在 HIV 患者中，使用高效抗逆转录病毒治疗（HAART）与氧化应激相关的线粒体功能障碍之间可能存在关联。我们评估了 HIV 患者在短期和长期治疗后短期和长期接受 HAART 治疗对线粒体和氧化的影响。
招募了 96 名患者，分为四组，每组 24 人。第 1 组为年龄匹配的、明显健康的、血清阴性个体（无 HIV 组）；第 2 组由未开始任何形式治疗的 HIV 血清阳性个体组成（治疗初治组）。第 3 组为接受 HAART 治疗不足一年的已知 HIV 患者（短期治疗组），第 4 组为接受 HAART 治疗超过一年的 HIV 患者（长期治疗组）。所有患者年龄在 18 至 60 岁之间，在研究时均在 HIV 诊所就诊。使用标准操作程序测定总抗氧化状态（TAS，nmol/L）、丙二醛（MDA，mmol/L）、CD4+细胞/μl 计数和基因组研究。
我们发现，与短期治疗组和无 HIV 组相比，长期治疗组的 MDA 水平显著升高，TAS 显著降低（P<0.05）。此外，长期治疗组线粒体基因（mtDNA：D-环、ATPase 8、TRNALEU uur）的拷贝数显著升高。
长期接受 HAART 治疗会增加 HIV 患者的氧化应激并导致线粒体改变。
